ATH434 reduced functional decline vs placebo at Week 52 on MuSyCA, a newly described MSA composite scale -- Effects seen on both daily function ...
Cenrifki prevents MS disease progression and Itvisma delivers a healthy gene-to-cell nuclei, addressing the root cause of SMA.
Ametefgene parvec (AB-1005) manufactured at Viralgen commercial manufacturing facility with next-generation process to deliver high-purity product with greater efficiency AskBio Inc. (AskBio), a ...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced additional positive results from the pivotal study of zilganersen in children and adults living with Alexander disease (AxD), a rare, ...
A new UK-wide research collaboration acclerating development of promising new treatments and precision diagnostics for ...
After a series of regulatory and clinical setbacks for Sanofi’s tolebrutinib, the French pharma has scored a victory for the ...
If approved, Itvisma (intrathecal onasemnogene abeparvovec) will be first and only gene replacement therapy for children two ...
A new national research collaboration designed to speed up the development of promising new treatments and precision ...
Stockhead on MSN
Lunch Wrap: ASX wobbles as war uncertainty brews; Cochlear clipped in brutal sell-off
Markets are looking wobbly again midweek as the Hormuz blockade lingers despite ceasefire talk. ... Read More The post Lunch ...
The Phase II trial enrolled 129 participants, of whom 94% had relapsing remitting multiple sclerosis, and 6% had secondary ...
Study published in SCIE-indexed international journal Molecular Neurobiology; Three intravenous infusions at four-week ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results